Baylor University Medical Center Proceedings April 2014, Volume 27, Number 2 | Page 116

283. Boostrom SY, Mathis KL, Pendlimari R, Cima RR, Larson DW, Dozois
EJ. Risk of neoplastic change in ileal pouches in familial adenomatous
polyposis. J Gastrointest Surg 2013;17(10):1804–1808.
284. Boostrom SY, Nelson H. Current treatment of rectal cancer: the
watch and wait method. Are we there yet? Sem Colon Rectal Surg
2013;24(3):147–150.
285. Bredeson C, Lerademacher J, Kato K, Dipersio JF, Agura E, Devine
SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy
PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM,
Pasquini MC. Prospective cohort study comparing intravenous busulfan
to total body irradiation in hematopoietic cell transplantation. Blood
2013;122(24):3871–3878.
286. Burch M, Schneider R, Barakat A, Abushahin L, Cao Y, Ewing J, Stone
MJ. Results of an educational program to promote the use of pooled
instead of single-donor platelet transfusions. Proc (Bayl Univ Med Cent)
2013;26(1):3–5.
287. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J,
Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of
chemoradiotherapy for anaplastic oligodendroglioma: long-term results
of RTOG 9402. J Clin Oncol 2013;31(3):337–343.
288. Chamogeorgakis T, Bhora F, Toumpoulis I, Nabong A, Connery C. Effect
of postoperative course on midterm outcome after esophageal resection
for cancer. Proc (Bayl Univ Med Cent) 2013;26(3):239–242.
289. Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Kimryn
Rathmell W, McDermott DF, Stadler WM. FDG-PET as a predictive
biomarker for therapy with everolimus in metastatic renal cell cancer.
Cancer Med 2013;2(4):545–552.
290. Cheng YS, Jordan L, Rees T, Chen HS, Oxford L, Brinkmann O, Wong
D. Levels of potential oral cancer s Ɨf'